Immunovaccine’s Lead Immuno-Oncology Candidate to Enter Investigator-Sponsored Phase 2 Clinical Trial in DLBCL in Combination with Approved Anti-PD-1 Drug
HALIFAX, NOVA SCOTIA–(Marketwired – May 16, 2017) – Immunovaccine Inc. (TSX:IMV)(OTCQX:IMMVF), a clinical stage vaccine and immuno-oncology company, today announced […]